TARA
Protara Therapeutics, Inc.
$3.97
-1.73%
$227.1M
No data for this timeframe.
Vol
Market Cap$227.1M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (93%)
Inst. Holders8 funds
Inst. Value$18.7M
Inst. Activity6 buys / 0 sells
Insider Activity0B / 2S
Insider Net $-$125.0K
SEC Reports11
Press Releases2
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·CIK 0001359931·Prev Close $4.04
Recent Activity
Jun 2, 2026
Insider
CONKLING WILLIAM sold 6,008 shares
Chief Commercial Officer @ $4.34 ($26.1K)
May 22, 2026
short_volume
Short Volume: TARA — 71.1% short (0.5M / 0.7M)
Short: 522,948 | Exempt: 0 | TRF Vol: 735,651 | Short Ratio: 71.1% | Off-exchange volume (dark pool
May 15, 2026
Press
Protara Therapeutics announced positive updated 12-month data from its Phase 2 ADVANCED-2 trial of TARA-002 in BCG-Naïve
Impact 7/10
Apr 16, 2026
SEC
Jones Trading initiates TARA with a Buy rating and $21 price target, implying 295% upside from the current $5.31. The fi
ANALYST-UPGRADE — Impact 9/10
Apr 16, 2026
SEC
Piper Sandler initiates coverage on TARA with an Overweight rating and $24 price target, implying 353% upside from the c
ANALYST-UPGRADE — Impact 8/10
Apr 16, 2026
SEC
JP Morgan initiates coverage on TARA with an Overweight rating and $27 price target, implying 409% upside from the curre
ANALYST-UPGRADE — Impact 8/10
Apr 8, 2026
Insider
Zummo Jacqueline sold 1,134 shares
Chief R&D Officer @ $5.40 ($6.1K)
Apr 1, 2026
Insider
Zummo Jacqueline sold 22,598 shares
Chief R&D Officer @ $5.26 ($118.9K)
Price Targets
$26.57
+569.3% upside
Strong Buy
Current $3.97
Low $24.00
Median $26.00
High $30.00
7 analysts
$24.00
$30.00
Analyst Ratings
3Strong Buy
10Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 20, 2026 | Oppenheimer | MAINTAIN | Outperform → Outperform |
| May 14, 2026 | JP Morgan | MAINTAIN | Overweight → Overweight |
| Apr 29, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Mar 4, 2026 | JP Morgan | INITIATE | Overweight |
| Feb 10, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.31 ▲ +18.8% | $-0.35 — $-0.25 | 11% YoY | 6 |
| Next Q | $-0.33 ▲ +14.7% | $-0.38 — $-0.26 | -6% YoY | 6 |
| Current FY | $-1.40 ▲ +8.9% | $-2.10 — $-1.02 | -4% YoY | 8 |
| Next FY | $-1.53 ▼ -10.3% | $-2.25 — $-1.13 | -10% YoY | 7 |
Latest Reports
BULLISH
Press
7/10
Protara Therapeutics announced positive updated 12-month data from its Phase 2 ADVANCED-2 trial of TARA-002 in BCG-Naïve
May 15, 2026
BULLISH
ANALYST-UPGRADE
8/10
Piper Sandler initiates coverage on TARA with an Overweight rating and $24 price target, implying 353% upside from the c
Apr 16, 2026
BULLISH
ANALYST-UPGRADE
8/10
JP Morgan initiates coverage on TARA with an Overweight rating and $27 price target, implying 409% upside from the curre
Apr 16, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $12.7M | ADD |
| BANK OF AMERICA CORP | $2.6M | DOUBLED |
| RENAISSANCE TECHNOLOGIES LLC | $1.4M | DOUBLED |
| MORGAN STANLEY | $934.5K | ADD |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $546.3K | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 2, 2026 | CONKLING WILLIAM | F | $26.1K |
| Apr 8, 2026 | Zummo Jacqueline | SELL | $6.1K |
| Apr 1, 2026 | Zummo Jacqueline | SELL | $118.9K |
8 institutional holders with $18.7M total value (3,505,789 shares) as of 2025-Q4. Top holders: VANGUARD, BANK, RENAISSANCE. Net buying activity: 6 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 2,391,903 | $12.7M | 68.2% | ADD +25.6% |
| 2 | BANK OF AMERICA CORP /DE/ | 495,904 | $2.6M | 14.1% | DOUBLED +174.8% |
| 3 | RENAISSANCE TECHNOLOGIES LLC | 266,807 | $1.4M | 7.6% | DOUBLED +110.7% |
| 4 | MORGAN STANLEY | 175,329 | $934.5K | 5.0% | ADD +61.5% |
| 5 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 102,499 | $546.3K | 2.9% | DOUBLED +538.5% |
| 6 | WELLS FARGO & COMPANY/MN | 39,802 | $212.1K | 1.1% | ADD +60.7% |
| 7 | TWO SIGMA INVESTMENTS, LP | 32,662 | $174.1K | 0.9% | ADD +67.0% |
| 8 | FMR LLC | 883 | $4.7K | 0.0% | DOUBLED +849.5% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | ADD | 1,904,156 | 2,391,903 | +25.6% | $12.7M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 180,475 | 495,904 | +174.8% | $2.6M | 2025-Q4 |
| MORGAN STANLEY | ADD | 108,544 | 175,329 | +61.5% | $934.5K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 24,765 | 39,802 | +60.7% | $212.1K | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | ADD | 19,558 | 32,662 | +67.0% | $174.1K | 2025-Q4 |
| FMR LLC | DOUBLED | 93 | 883 | +849.5% | $4.7K | 2025-Q4 |
| UBS Group AG | TRIM | 1,135,767 | 843,074 | -25.8% | $3.7M | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 149,200 | 314,300 | +110.7% | $1.4M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | ADD | 14,404 | 19,558 | +35.8% | $85.1K | 2025-Q3 |
| UBS Group AG | ADD | 636,674 | 1,135,767 | +78.4% | $3.4M | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | TRIM | 288,717 | 181,600 | -37.1% | $550.2K | 2025-Q2 |
| MORGAN STANLEY | ADD | 66,215 | 128,915 | +94.7% | $390.6K | 2025-Q2 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | DOUBLED | 15,000 | 95,774 | +538.5% | $290.2K | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | NEW | — | 20,727 | — | $62.8K | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 23,590 | 14,404 | -38.9% | $43.6K | 2025-Q2 |
| UBS Group AG | DOUBLED | 149,408 | 636,674 | +326.1% | $2.7M | 2025-Q1 |
| CITADEL ADVISORS LLC | TRIM | 1,084,134 | 460,631 | -57.5% | $2.0M | 2025-Q1 |
| MORGAN STANLEY | TRIM | 99,527 | 66,215 | -33.5% | $282.1K | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | ADD | 13,633 | 23,590 | +73.0% | $100.5K | 2025-Q1 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 15,000 | — | $63.9K | 2025-Q1 |
| CITADEL ADVISORS LLC | ADD | 691,311 | 1,084,134 | +56.8% | $5.7M | 2024-Q4 |
| UBS Group AG | DOUBLED | 7,418 | 149,408 | +1914.1% | $788.9K | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 336,740 | 142,300 | -57.7% | $751.3K | 2024-Q4 |
| MORGAN STANLEY | NEW | — | 99,527 | — | $525.5K | 2024-Q4 |
2 unique insiders with 2 transactions. Net insider value: -$125.0K ($0.00 bought, $125.0K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 2, 2026 | CONKLING WILLIAM | Chief Commercial Officer | F | 6,008 | $4.34 | $26.1K |
| Apr 8, 2026 | Zummo Jacqueline | Chief R&D Officer | SELL | 1,134 | $5.40 | $6.1K |
| Apr 1, 2026 | Zummo Jacqueline | Chief R&D Officer | SELL | 22,598 | $5.26 | $118.9K |
11 SEC filing reports analyzed. Sentiment: 6 bullish, 1 bearish, 1 mixed, 3 neutral. Avg impact: 5.9/10.
BULLISH
ANALYST-UPGRADE
8/10
JP Morgan initiates coverage on TARA with an Overweight rating and $27 price target, implying 409% u
Apr 16, 2026
BULLISH
ANALYST-UPGRADE
8/10
Piper Sandler initiates coverage on TARA with an Overweight rating and $24 price target, implying 35
Apr 16, 2026
BULLISH
ANALYST-UPGRADE
9/10
Jones Trading initiates TARA with a Buy rating and $21 price target, implying 295% upside from the c
Apr 16, 2026
MIXED
ANALYST-UPGRADE
6/10
Scotiabank initiates TARA with Sector Outperform and a $12 price target, implying 126% upside from t
Apr 16, 2026
BULLISH
ANALYST-UPGRADE
8/10
Cantor Fitzgerald initiates coverage on TARA with an Overweight rating, joining JPMorgan and Piper S
Apr 16, 2026
BULLISH
ANALYST-UPGRADE
8/10
LifeSci Capital initiates coverage on TARA with an Outperform rating and $22 price target, implying
Apr 16, 2026
BULLISH
ANALYST-UPGRADE
3/10
JP Morgan maintains Overweight on TARA — PT $26, 391% upside as consensus remains heavily bullish
May 16, 2026
BEARISH
EFFECT
5/10
Protara Therapeutics' registration statement on Form S-3 (File No. 333-295862) was declared effectiv
May 26, 2026
NEUTRAL
8-K
4/10
Protara Therapeutics reported Q1 2026 net loss of $17.8M ($0.31/sh), beating the $-0.36 consensus by
May 13, 2026
NEUTRAL
PRESS-RELEASE
4/10
Protara Therapeutics reported Q1 2026 net loss of $0.31 per share, beating consensus estimates of $0
May 13, 2026
NEUTRAL
DEFA14A
2/10
Protara Therapeutics filed definitive additional proxy materials for its 2026 Annual Meeting of Stoc
Apr 28, 2026
Current analyst consensus: Strong Buy (93% buy). Based on 14 analysts: 3 strong buy, 10 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$26.57 mean target
+569.3% upside
Strong Buy (3.00)
$24.00 Low
$30.00 High
| Metric | Value |
|---|---|
| Current Price | $3.97 |
| Target Low | $24.00 |
| Target Mean | $26.57 |
| Target Median | $26.00 |
| Target High | $30.00 |
| # Analysts | 7 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.31 | $-0.35 | $-0.25 | 10.6% | +18.8% | 4↑ 0↓ | $0.0B | 0.0% | 6 |
| Next Q 2026-09-30 |
$-0.33 | $-0.38 | $-0.26 | -5.7% | +14.7% | 4↑ 0↓ | $0.0B | 0.0% | 6 |
| Current FY 2026-12-31 |
$-1.40 | $-2.10 | $-1.02 | -4.4% | +8.9% | 5↑ 0↓ | $0.0B | 0.0% | 8 |
| Next FY 2027-12-31 |
$-1.53 | $-2.25 | $-1.13 | -9.6% | -10.3% | 4↑ 1↓ | $0.0B | 0.0% | 7 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.313 | |
| 7d ago | $-0.341 | +0.028 |
| 30d ago | $-0.386 | +0.073 |
| 60d ago | $-0.386 | +0.073 |
| 90d ago | $-0.358 | +0.045 |
4 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 2 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 20, 2026 | Oppenheimer | MAINTAIN | Outperform | Outperform |
| May 14, 2026 | JP Morgan | MAINTAIN | Overweight | Overweight |
| Apr 29, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 4, 2026 | JP Morgan | INITIATE | — | Overweight |
| Feb 10, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jan 7, 2026 | Piper Sandler | INITIATE | — | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 10 | 1 | 0 | 0 | 93% | |
| May 1, 2026 | 3 | 10 | 1 | 0 | 0 | 93% | |
| Apr 1, 2026 | 3 | 10 | 1 | 0 | 0 | 93% | |
| Mar 1, 2026 | 3 | 9 | 1 | 0 | 0 | 92% | |
| Feb 1, 2026 | 3 | 9 | 1 | 0 | 0 | 92% | |
| Jan 1, 2026 | 3 | 8 | 1 | 0 | 0 | 92% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 22, 2026
short_volume
Short Volume: TARA — 71.1% short (0.5M / 0.7M)
Short: 522,948 | Exempt: 0 | TRF Vol: 735,651 | Short Ratio: 71.1% | Off-exchange volume (dark pool + OTC)
May 21, 2026
short_volume
Short Volume: TARA — 81.2% short (1.3M / 1.6M)
Short: 1,318,237 | Exempt: 0 | TRF Vol: 1,623,584 | Short Ratio: 81.2% | Off-exchange volume (dark pool + OTC)
May 15, 2026
fda
Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBC
<p align="center"> <em>TARA-002 demonstrates 72% complete response rate at any time, 67% complete response rate at the 6-month landmark and 55% c
May 13, 2026
earnings
Protara Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update
<p align="center"><em>The Company intends to submit a Biologics License Application (BLA) for TARA-002 in Lymphatic Malformations (LMs) in 2H 2027</em
Apr 30, 2026
earnings_calendar
TARA Q1 2026 Earnings Scheduled — 2026-04-30
Apr 27, 2026
routine
Protara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual Meeting
<p align="justify">NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc.<strong> </strong>(Nasdaq: TARA), a clinical-stage biotech
Mar 11, 2026
earnings_calendar
TARA Q4 2025 Earnings After Market Close — 2026-03-11
Mar 10, 2026
earnings
Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
<p align="center"><em>Reported interim data from ADVANCED-2 trial in non-muscle invasive bladder cancer (NMIBC); TARA-002 demonstrated 68% complete re